Navigation Links
Enzyme weakens the heart
Date:2/17/2009

An enzyme makes the mouse heart prone to chronic cardiac insufficiency if it is suppressed, the heart remains strong despite increased stress. Cardiologists at the Internal Medicine Clinic at Heidelberg University Hospital in cooperation with scientists at the University of Texas Southwestern Medical Center at Dallas and Gttingen University Hospital have now explained this key mechanism in a mouse model and thus discovered a promising approach for the systematic prevention of chronic cardiac insufficiency. The study has now been published online before print in the prestigious journal Proceedings of the National Academy of Sciences.

Long-term high pressure and stenoses of the valves or aorta make the heart work harder. When it compensates by excessive muscle growth (cardiac hypertrophy), the pump function is affected rhythm disorders or heart failure can be the result. Other risk factors are overweight and age more than 40 percent of people over age 70 suffer from cardiac muscle hypertrophy.

Despite progress in medication, around 95,000 people in Germany die annually from the consequences of chronic cardiac insufficiency. "It is essential to find the molecules that are key to the development of cardiac insufficiency in order to develop new, more efficient treatment" states Dr. Johannes Backs, head of a research group in the Department of Cardiology, Angiology, and Pneumonology (Director Prof. Dr. med. Hugo A. Katus) at Heidelberg University Hospital.

Enzyme activates stress response and hypertrophy of the heart

A key molecule for cardiac hypertrophy brought on by stress is the naturally occurring enzyme CaMKII delta (Calcium/Calmodulin-dependent kinase II delta). Dr. Backs' international research team proved this in genetically modified mice that could no longer produce this enzyme by surgically obstructing the main aorta to put the heart under greater stress and thus simulate permanent high blood pressure or valve stenosis in humans. The anticipated enlargement of the heart was very slight the animals were protected.

"With these mice, we succeeded for the first time in specifically suppressing the CaMKII delta enzyme and clarifying its function in detail," said Dr. Backs. CaMKII delta has a direct effect on the cells' stress response. If it is missing, certain information in cell DNA is not accessed that is normally activated by stress, leading to hypertrophy of the heart. "There was still some slight enlargement of the heart, but presumably not enough to cause cardiac insufficiency," said Dr. Backs. Under normal conditions, the genetically modified mice are inconspicuous their hearts function and react normally.

The function of CaMKII delta as an intermediate of the heart's stress response is a possible approach for effective therapy the Heidelberg researchers anticipate that agents that block only this function of the enzyme would prevent the heart muscle from reacting to overload. Other functions of CaMKII delta should not be affected in order to avoid harmful side effects.


'/>"/>

Contact: Dr. Johannes Backs
johannes.backs@med.uni-heidelberg.de
49-622-156-37714
University Hospital Heidelberg
Source:Eurekalert

Related medicine news :

1. Durability of dental fillings improves if the enzyme activity of teeth is inhibited
2. Unique Glutathione Reductase Enzyme Introduced by Bio-Research Products
3. Enzyme with a sugar antenna
4. Low Levels of 2 Enzymes in Ovarian Cancer Cells Shortened Survival
5. Millennium Research Group Analyst Available to Comment on FDAs Premarket Approval Recommendation of Genzyme Biosurgerys Synvisc Single-Injection Product for the Knee
6. Scientists ID Enzyme Causing Brain Cell Death
7. Researchers discover new enzyme in cancer growth
8. Broccoli compound targets key enzyme in late-stage cancer
9. IDO2 an active enzyme to target in pancreatic cancer
10. Genetic disorder sheds light on enzymes role in bone metabolism
11. AUDIO from Medialink and Genzyme: Study in New England Journal of Medicine Shows Investigational Compound Reduced Relapses and Disability in Patients With MS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental ... Your Mouth?” (WIYM) campaign to inform dentists and patients about the safety issues related ... and prosthetic market in the U.S. is projected to reach $6.4 billion in 2018 ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... technologies and development solutions for drugs, biologics and consumer health products, today announced ... was set up in 2006 as a non-profit organization to unite pharmaceutical and ...
(Date:12/8/2016)... ... 08, 2016 , ... Healthcare is in flux. The GOP ... the mass media launching of story movements to highlight what's most unfair about ... experiences; such a movement can generate the network power to improve healthcare policies ...
(Date:12/8/2016)... ... December 08, 2016 , ... Peter Zipp Insurance, an ... around the greater Phoenix metropolitan region, is announcing a charity event to provide ... the Homeless Youth Connection is to promote community awareness of the ongoing needs ...
(Date:12/7/2016)... ... 07, 2016 , ... DrugDev again demonstrated its dedication to reducing ... the early adopters completing EU-U.S. Privacy Shield Certification from the U.S. Department of Commerce. ... sides of the Atlantic with a mechanism to comply with EU data protection requirements ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 2016   TriNetX , the health research ... signed a membership agreement to join the ... new cures. The TriNetX network is ... patients globally, biopharmaceutical companies and contract research organizations ... design, site selection, patient recruitment, and collaborative research ...
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals International, ... VRX) ("Valeant") today announced positive results from a ... to assess the safety and efficacy of IDP-118 ... of plaque psoriasis. Within the ... moderate to severe psoriasis, IDP-118 showed statistical significance ...
(Date:12/8/2016)... 8, 2016  EIP Pharma, LLC ( www.eippharma.com ... for neflamapimod (previously code named VX-745), with the ... trials that demonstrated significant Alzheimer,s disease relevant pharmacological ... and Study 303 (6-week treatment) are the subject ... Disease (CTAD) scientific conference in San ...
Breaking Medicine Technology: